Goal
Treat Covid-19 patients by delivering inhaled budesonide (and optionally formoterol) to reduce respiratory inflammation and mortality.
Problem
High death rates from Covid-19 respiratory disease and lack of inexpensive, widely available treatments.
Concept Summary
The article promotes the use of an inhaled corticosteroid (budesonide), delivered via a nebulizer, as a cheap, rapid solution for Covid-19. The author cites anecdotal success in Taiwan, Japan and Singapore, claiming a 100 % survival rate among treated patients.
Principles
- Anti-inflammatory action of corticosteroids
- Nebulization for aerosol delivery to the lungs
- Bronchodilation (when combined with formoterol)
Scientific Domains
Materials
- Budesonide
- Formoterol
- Saline solution
Mechanisms of Action
- Inhaled budesonide binds glucocorticoid receptors, suppressing cytokine production and airway inflammation
- Formoterol (if present) activates beta2-adrenergic receptors, causing bronchodilation
Applications
- Covid-19 treatment
- Asthma and COPD management
Claimed Performance
100 % of the author's Covid-19 patients survived; low national death counts (e.g., 7 deaths in Taiwan) attributed to widespread budesonide inhalation.
Experimental Evidence
The article provides anecdotal statements from Dr. Richard Bartlett (e.g., "A hundred percent of my (Covid-19) patients are alive") but no quantitative trial data, peer-reviewed studies, or independent replication.
Limitations
- Lack of controlled clinical trial data
- Reliance on anecdotal reports
- Potential side-effects of inhaled steroids (e.g., oral candidiasis, throat irritation)
Red Flags
- Claims of 100 % survival without peer-reviewed evidence
- Possible over-statement of efficacy ("silver bullet")
- No independent replication or statistical data presented
